OA11040A - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations Download PDF

Info

Publication number
OA11040A
OA11040A OA9900091A OA9900091A OA11040A OA 11040 A OA11040 A OA 11040A OA 9900091 A OA9900091 A OA 9900091A OA 9900091 A OA9900091 A OA 9900091A OA 11040 A OA11040 A OA 11040A
Authority
OA
OAPI
Prior art keywords
préparation
free base
binder
tablet
siidénafil
Prior art date
Application number
OA9900091A
Other languages
English (en)
Inventor
Cristi Bell-Huff
Thomas Francis Dolan
Angela Carol Gatlin Hausberger
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA11040A publication Critical patent/OA11040A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicon Polymers (AREA)
OA9900091A 1998-05-15 1999-04-30 Pharmaceutical formulations OA11040A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8564698P 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
OA11040A true OA11040A (en) 2003-01-01

Family

ID=22193027

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900091A OA11040A (en) 1998-05-15 1999-04-30 Pharmaceutical formulations

Country Status (32)

Country Link
US (1) US20020002172A1 (hr)
EP (1) EP0960621A3 (hr)
JP (1) JPH11349483A (hr)
KR (1) KR19990088249A (hr)
CN (1) CN1251758A (hr)
AP (1) AP9901534A0 (hr)
AR (1) AR016481A1 (hr)
AU (1) AU753478B2 (hr)
BG (1) BG103396A (hr)
BR (1) BR9902086A (hr)
CA (1) CA2272042A1 (hr)
CO (1) CO5060503A1 (hr)
DZ (1) DZ2786A1 (hr)
EA (1) EA002830B1 (hr)
GT (1) GT199900061A (hr)
HN (1) HN1999000066A (hr)
HR (1) HRP990144A2 (hr)
HU (1) HUP9901606A2 (hr)
ID (1) ID23299A (hr)
IS (1) IS5046A (hr)
MA (1) MA26629A1 (hr)
NO (1) NO992339L (hr)
NZ (1) NZ335772A (hr)
OA (1) OA11040A (hr)
PA (1) PA8472901A1 (hr)
PE (1) PE20000546A1 (hr)
PL (1) PL333118A1 (hr)
SG (1) SG79255A1 (hr)
SK (1) SK61599A3 (hr)
TR (1) TR199901077A3 (hr)
YU (1) YU21999A (hr)
ZA (1) ZA993338B (hr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020033A1 (fr) * 1998-10-05 2000-04-13 Eisai Co., Ltd. Comprimes se delitant immediatement dans la cavite buccale
WO2000053148A2 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
AU3744800A (en) * 1999-03-16 2000-10-04 Pentech Pharmaceuticals, Inc. Controlled release of sildenafil delivered by sublingual or buccal administration
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
KR100344198B1 (ko) * 1999-10-08 2002-07-19 일양약품주식회사 실데나필 시트레이트의 속효제형
NZ524572A (en) * 2000-09-06 2004-08-27 Tanabe Seiyaku Co Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
IN192750B (hr) * 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US6544552B2 (en) * 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
EP1226818A1 (en) * 2001-01-26 2002-07-31 Pfizer Products Inc. Pharmaceutical dosage forms with enhanced cohesive and compressibility properties
MXPA03010119A (es) * 2001-05-09 2005-03-07 Bayer Healthcare Ag Nuevo uso de imidazotriazinonas 2-fenilo sustituidas.
LV12978B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
KR20040037138A (ko) * 2001-09-28 2004-05-04 가부시키가이샤산와카가쿠켄큐쇼 유핵형 속용붕괴성 성형품
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
US7278982B2 (en) 2003-03-27 2007-10-09 Bioactis Limited Powder medicine applicator for nasal cavity
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
EP1785145A4 (en) * 2004-08-10 2008-08-13 Translational Res Ltd TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
MX2008000087A (es) * 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
CA2623657A1 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
WO2008078730A1 (ja) 2006-12-26 2008-07-03 Translational Research, Ltd. 経鼻投与用製剤
BRPI0807281A2 (pt) * 2007-02-12 2014-04-29 Dmi Biosciences Inc Reduzindo os efeitos colaterais de tramadol
CN101711153A (zh) * 2007-06-13 2010-05-19 拜耳先灵制药股份公司 用于治疗听觉损伤的pde抑制剂
FR2932682B1 (fr) * 2008-06-23 2013-07-12 Bionetwork Nouvelles formes pharmaceutiques a effet rapide et les utilisations des compositions pharmaceutiques ainsi obtenus.
ES2588429T3 (es) * 2009-03-09 2016-11-02 Spi Pharma, Inc. Excipientes y sistemas de excipientes de compresión directa altamente compactables y durables
DE102009016584A1 (de) 2009-04-06 2010-10-07 Ratiopharm Gmbh Schmelztablette, enthaltend ein Sildenafil-Salz
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
EP2338474A1 (de) * 2009-12-23 2011-06-29 Ratiopharm GmbH Oral dispersible Tablette enthaltend kompaktierte Sildenafil-Base
DE102010024866A1 (de) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulierung zur Geschmacksmaskierung
AU2012214939B2 (en) * 2011-02-11 2016-11-17 Ctc Bio, Inc. Sildenafil-free base-containing film preparation and method for producing same
KR101418406B1 (ko) * 2011-08-24 2014-07-10 한미약품 주식회사 실데나필 유리 염기를 포함하는 구강 붕해정
MX366768B (es) * 2011-12-08 2019-07-17 Laboratorios Liomont S A De C V Tableta orodispersable de sildenafil y metodo para preparar la misma.
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
CN105769887B (zh) * 2014-12-23 2019-04-30 上海复星星泰医药科技有限公司 一种复方果糖二磷酸钠果糖口崩片及其制备方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN114246835A (zh) * 2022-01-05 2022-03-29 河北龙海药业有限公司 一种枸橼酸西地那非口腔崩解片的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246013A1 (de) * 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DE19532142A1 (de) * 1995-08-31 1997-03-06 Siemens Ag Verfahren und Vorrichtung zur Regelung eines vierdimensionalen Vektors einer Strecke mittels eines wertediskreten Stellgliedes mit begrenzter Schaltfrequenz
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
AU739417B2 (en) * 1997-05-29 2001-10-11 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for erection dysfunction
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
AU3744800A (en) * 1999-03-16 2000-10-04 Pentech Pharmaceuticals, Inc. Controlled release of sildenafil delivered by sublingual or buccal administration

Also Published As

Publication number Publication date
EA199900373A2 (ru) 1999-12-29
SK61599A3 (en) 2000-12-11
YU21999A (sh) 2002-03-18
TR199901077A2 (en) 1999-12-21
ID23299A (id) 2000-04-05
PA8472901A1 (es) 2000-09-29
AR016481A1 (es) 2001-07-04
CO5060503A1 (es) 2001-07-30
TR199901077A3 (tr) 1999-12-21
US20020002172A1 (en) 2002-01-03
SG79255A1 (en) 2001-03-20
MA26629A1 (fr) 2004-12-20
CA2272042A1 (en) 1999-11-15
PE20000546A1 (es) 2000-07-07
HRP990144A2 (en) 2000-02-29
BG103396A (bg) 2000-01-31
BR9902086A (pt) 2000-05-02
HN1999000066A (es) 1999-09-29
HUP9901606A2 (en) 2002-09-28
EP0960621A3 (en) 2000-01-05
KR19990088249A (ko) 1999-12-27
GT199900061A (es) 2000-10-14
HU9901606D0 (en) 1999-07-28
NZ335772A (en) 2000-12-22
AU753478B2 (en) 2002-10-17
NO992339D0 (no) 1999-05-14
PL333118A1 (en) 1999-11-22
JPH11349483A (ja) 1999-12-21
IS5046A (is) 1999-11-16
CN1251758A (zh) 2000-05-03
EA002830B1 (ru) 2002-10-31
EA199900373A3 (ru) 2000-08-28
AU2812699A (en) 1999-11-25
DZ2786A1 (fr) 2003-12-01
EP0960621A2 (en) 1999-12-01
ZA993338B (en) 2000-11-14
NO992339L (no) 1999-11-16
AP9901534A0 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
OA11040A (en) Pharmaceutical formulations
RU2436565C2 (ru) Распадающиеся пероральные пленки
TWI288002B (en) Orally disintegrating tablets and process for obtaining them
US6455053B1 (en) Quickly soluble solid preparations
EP0542824B1 (fr) Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee
JP5209492B2 (ja) 速崩性錠剤製造のための医薬製剤
US6187336B1 (en) Process for producing a solid which is rapidly soluble in the oral cavity
EP1246668B1 (en) An rapid acting freeze dired oral pharmaceutical composition for treating migraine
TWI387465B (zh) 具有改良之藥物動力學性質之藥物配製物
US20020001617A1 (en) Rapidly disintegrating tablet and process for the manufacture thereof
CA2440361A1 (en) Intraorally rapidly disintegrable preparation
EP1121103A2 (en) Orally disintegrable tablets
JP2003531161A (ja) 発泡性顆粒剤およびその調製法
JP4074675B2 (ja) トラマドール又はトラマドール塩の急速に崩壊する薬剤形
KR20090043528A (ko) 알리스키렌의 갈레닉 제제
KR20070118247A (ko) 쓴맛이 저감된 프란루카스트 수화물을 함유하는 제제
JP2005523256A (ja) ペリンドプリルの口内分散性薬剤組成物
JP2003261439A (ja) 口腔内崩壊製剤
US20150335581A1 (en) Orodispersible tablets obtained by compression molding
KR100503949B1 (ko) 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
JP2006528160A (ja) 抗血栓性化合物の口腔分散性医薬組成物
WO2014092358A1 (en) Chewable tablet comprising a phosphodiesterase-5 inhibitor
JPH11116464A (ja) 迅速溶解性固形製剤およびその製造法
CZ159199A3 (cs) Farmaceutický přípravek rozpadající se v ústech a způsob léčení sexuální dysfunkce
US20080057121A1 (en) Pharmaceutical Composition and Galenic Form Corresponding to Rapid Oral Disintegration and Method for Production of Said Composition